StockNews.AI
JAGX
StockNews.AI
209 days

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

1. Jaguar's crofelemer trial may enable early European access for MVID treatment. 2. The FDA has granted Orphan Drug Designation for crofelemer, enhancing market potential.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive trial data could boost JAGX's stock price, similar to prior FDA approvals.

How important is it?

The study's outcomes could directly influence JAGX's market viability and revenue potential.

Why Long Term?

If successful, the trial results may catalyze sustained growth over years.

Related Companies

JAGXNapo
Trial taking place at Sheikh Khalifa Medical City , a flagship tertiary hospital in the United Arab Emirates POC data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for MVID Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome with intestinal failure (SBS-IF) SAN FRANCISCO, CA / ACCESS Newswire / January 22, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first patient has been dosed in the independent investigator-initiated POC trial of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of MVID in pediatric patients. POC data generated from this study potentially in the first half of 2025 could lead to reimbursed early patient access to crofelemer for this indication in certain European countries.

Related News